State Board of Administration of Florida Retirement System raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 115,325 shares of the biopharmaceutical company’s stock after buying an additional 1,087 shares during the period. State Board of Administration of Florida Retirement System owned approximately 0.11% of Regeneron Pharmaceuticals worth $56,641,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in REGN. BlackRock Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 5,121,496 shares of the biopharmaceutical company’s stock worth $1,984,630,000 after buying an additional 199,975 shares during the last quarter. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock worth $1,309,861,000 after buying an additional 139,602 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its position in shares of Regeneron Pharmaceuticals by 2.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock worth $749,145,000 after buying an additional 41,630 shares during the last quarter. 67.16% of the stock is owned by institutional investors.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at 467.98 on Monday. The firm has a 50-day moving average price of $489.51 and a 200-day moving average price of $430.92. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The firm has a market capitalization of $49.62 billion, a PE ratio of 46.95 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current fiscal year.
A number of equities analysts have commented on the company. UBS AG set a $489.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research report on Monday, May 15th. Piper Jaffray Companies upped their price target on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research report on Tuesday, June 20th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $472.00 price target (up from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $471.00 price target (up from $418.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $495.59.
In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares in the company, valued at approximately $23,405,572.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the completion of the transaction, the chairman now owns 414,156 shares of the company’s stock, valued at approximately $189,741,429.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 84,404 shares of company stock valued at $40,303,792. 10.40% of the stock is owned by insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
